{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"59","value":"113.4"},{"groupId":"OG001","spread":"113","value":"174.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"title":"Cycle 1/Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"43","value":"127.9"},{"groupId":"OG001","spread":"37","value":"121.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"title":"Cycle 1/Day 2"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received oral doses of glasdegib tablets 100 mg starting on Day 2 of Cycle 1 for PK assessment purposes and thereafter QD and continuously for 28-day cycles (starting on Day 1 for all other cycles). Decitabine was given at a dose of 20 mg/m\\^2 as an intravenous (IV) infusion over 1 hour on Days 1-5 of the 28-day cycles.","id":"OG000","title":"Phase 1B: Glasdegib 100 mg + Decitabine"},{"description":"Participants received oral doses of glasdegib tablets 200 mg starting on Day 3 of Cycle 1 for PK assessment purposes and thereafter QD and continuously for 28-day cycles (starting on Day 1 for all other cycles). LDAC was given at a dose of 20 mg subcutaneously BID on Days 1-10 of the 28-day cycles. In March 2013, all active participants receiving glasdegib 200 mg were required to reduce dose to 100 mg. Participants who had glasdegib dose reduction were reported as the starting glasdegib dose level received. Two (2) participants in this cohort had dose reduction to 100 mg starting from Cycle 2/Day 1 and Cycle 2/Day 16, respectively.","id":"OG001","title":"Phase 1B: Glasdegib 200 mg + Decitabine"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK concentration population: all treated participants who had at least 1 concentration of any of the study drugs.","reportingStatus":"POSTED","timeFrame":"Pre-dose, 0.5 hour from start of infusion, 1 hour (at end of infusion) and 2, 3 and 4 hours from start of infusion on Cycle 1/Day 1 and Cycle 1/Day 2","title":"Cmax of Decitabine in Participants Receiving Glasdegib and Decitabine at Phase 1B on Cycle 1/Day 1 and Cycle 1/Day 2","type":"SECONDARY","unitOfMeasure":"ng/mL"}